LITS
Price:
$1.75
Market Cap:
$64.37M
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Industry
Biotechnology
IPO Date
2003-12-18
Stock Exchange
NASDAQ
Ticker
LITS
According to Lite Strategy, Inc.’s latest financial reports and current stock price. The company's current ROE is -27.11%. This represents a change of 144.21% compared to the average of -11.10% of the last 4 quarters.
The mean historical ROE of Lite Strategy, Inc. over the last ten years is -71.41%. The current -27.11% ROE has changed -62.04% with respect to the historical average. Over the past ten years (40 quarters), LITS's ROE was at its highest in in the September 2025 quarter at -3.24%. The ROE was at its lowest in in the June 2024 quarter at -55.74%.
Average
-71.41%
Median
-94.18%
Minimum
-129.30%
Maximum
53.84%
Discovering the peaks and valleys of Lite Strategy, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 24.45%
Maximum Annual ROE = 53.84%
Minimum Annual Increase = -274.92%
Minimum Annual ROE = -129.30%
| Year | ROE | Change |
|---|---|---|
| 2025 | -94.18% | -274.92% |
| 2024 | 53.84% | -141.64% |
| 2023 | -129.30% | 24.45% |
| 2022 | -103.89% | 24.39% |
The current ROE of Lite Strategy, Inc. (LITS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-56.54%
5-year avg
-71.41%
10-year avg
-71.41%
Lite Strategy, Inc.’s ROE is greater than TScan Therapeutics, Inc. (-63.84%), greater than Adicet Bio, Inc. (-68.48%), greater than Immunic, Inc. (-716.20%), greater than PMV Pharmaceuticals, Inc. (-47.95%), greater than Relmada Therapeutics, Inc. (-223.17%), greater than Nutriband Inc. (-131.40%), greater than Acrivon Therapeutics, Inc. Common Stock (-53.71%), greater than Werewolf Therapeutics, Inc. (-144.40%), greater than XBiotech Inc. (-16.73%), greater than IO Biotech, Inc. (-465.36%),
| Company | ROE | Market cap |
|---|---|---|
| -63.84% | $61.86M | |
| -68.48% | $46.22M | |
| -716.20% | $67.93M | |
| -47.95% | $68.11M | |
| -223.17% | $293.33M | |
| -131.40% | $56.47M | |
| -53.71% | $76.05M | |
| -144.40% | $48.35M | |
| -16.73% | $76.52M | |
| -465.36% | $48.79M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lite Strategy, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lite Strategy, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Lite Strategy, Inc.'s ROE?
How is the ROE calculated for Lite Strategy, Inc. (LITS)?
What is the highest ROE for Lite Strategy, Inc. (LITS)?
What is the 3-year average ROE for Lite Strategy, Inc. (LITS)?
What is the 5-year average ROE for Lite Strategy, Inc. (LITS)?
How does the current ROE for Lite Strategy, Inc. (LITS) compare to its historical average?